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Abstract Ghrelin is a recently identified endogenous ligand for the growth hormone secretagogue receptor.  It is 
synthesized predominantly in the stomach and found in the circulation of healthy humans.  Ghrelin has been shown to 
promote increased food intake, weight gain and adiposity in rodents.  The effect of ghrelin on appetite and food intake in man 
has not been determined.  We investigated the effects of intravenous ghrelin (5.0 pmol/kg/min) or saline infusion on appetite 
and food intake in a randomised double-blind cross-over study in nine healthy volunteers.  There was a clear-cut increase in 
energy consumed by every individual from a free-choice buffet (mean increase 28 ± 3.9%, p<0.001) during ghrelin compared 
with saline infusion.  Visual analogue scores for appetite were greater during ghrelin compared to saline infusion.  Ghrelin 
had no effect on gastric emptying as assessed by the paracetamol absorption test.  Ghrelin is the first circulating hormone 
demonstrated to stimulate food intake in man.  Endogenous ghrelin is a potentially important new regulator of the complex 
systems controlling food intake and body weight.   
_____________________________________________________________________________________________________ 
Introduction 
Obesity is a modern epidemic, which still has no 
effective medical treatment.  A very small percentage 
increase in energy intake over a long period of time can 
result in obesity (1).  In order to understand the 
pathophysiology of obesity it is necessary to investigate the 
physiology of normal body weight regulation.  Energy 
intake and body weight are tightly regulated at a remarkably 
consistent "set-point" by control systems in the 
hypothalamus (2).  These hypothalamic circuits receive 
feedback from peripheral signals.  The adipocyte-derived 
hormone leptin signals the state of fat stores to the brain, 
inhibiting food intake and further fat accumulation.  
Surprisingly no circulating stimulus to feeding and adiposity 
has been characterized (2).   
Ghrelin, like previous synthetic agonists of its 
receptor, is a growth hormone (GH) secretagogue (3;4).  In 
addition to this action, recent studies in rodents suggest that 
ghrelin may provide a peripheral signal to the brain to 
stimulate food intake and adiposity (5;6).  We have 
previously shown that, in rats, ghrelin stimulates food intake 
following systemic and intracerebroventricular 
administration (5).  In rodents, acute ghrelin administration 
has been shown to increase respiratory quotient (RQ) 
suggesting a switch towards glycolysis and away from fatty 
acid oxidation for energy expenditure, favouring fat 
deposition (6). Chronic ghrelin administration is also 
reported to cause weight gain and adiposity in rodents (6).   
We aimed to investigate the effect of ghrelin on 
food intake and energy expenditure in man.  Ghrelin is a 
gastric hormone and has been reported to stimulate gastric 
motility in rodents (7).  To investigate whether ghrelin might 
have any direct effects on the gastrointestinal tract in man, 
the effect of ghrelin on gastric emptying was also 
investigated. 
Research Design and Methods 
Materials:  Human ghrelin was obtained from Penninsula 
Laboratories, St Helens, Merseyside, UK.  The Limulus  
Amoebocyte Lysate assay test for pyrogen was negative and 
the peptide was sterile on culture.  Saline (0.9%) was 
purchased from Bayer, Haywards Heath, UK. 
Subjects:  Nine non-obese Caucasian volunteers (five male 
and four female) were recruited, aged 21-32 years (mean ± 
SEM, 25 ± 1.1), body mass index (BMI) 19.8-26.8 (23.2 ± 
0.7) kg/m2.  Ethical approval was obtained from the local 
Research Ethics Committee (project registration no. 
2000/5941) and the study was performed in accordance with 
the principles of the Declaration of Helsinki.  Subjects gave 
informed written consent, took no regular medication except 
oral contraceptive, had no allergies and had normal physical 
examination and electrocardiogram.  The Dutch Eating 
Behaviour Questionnaire (8) was used to exclude subjects 
with abnormal eating behaviour determined by high scores 
for restrained eating.  Blood tests confirmed normal renal 
and liver function, full blood count and fasting glucose.  
Volunteers filled out a food diary for three days prior to the 
cross-over infusions, and were required to maintain similar 
eating habits before each infusion.  All subjects were fasted 
and drank only water from 9pm on the evening prior to each 
study.  Subjects were advised to avoid alcohol and strenuous 
exercise for 24 hours before study. 
Protocol:  Fasted subjects had 2 intravenous cannulae (1 for 
infusion and 1 for sampling) placed at 08.00h and infusions 
commenced at 08.30h (0 min).  Blood samples were 
collected into plastic EDTA tubes containing 0.6mg 
aprotinin (Bayer).  Plasma was immediately separated by 
centrifugation at 4C and stored at -70C until assayed.  Basal 
blood samples were taken at -20 and 0 min.  The same 
subjects had an initial ghrelin infusion during which plasma 
samples were obtained for GH measurement by Advantage 
automated chemi-luminescent immunoassay (Nichols 
Institute Diagnostics).  Infusion was commenced at 
0.2pmol/kg/min.  Every 20 min samples were taken for GH 
measurement and infusion rate was doubled to a maximum 
of 25.6 pmol/kg/min.  The GH response was used to 
determine the infusion rate for the subsequent study. 
Cross-over study  The investigation protocol is summarized 
in figure 1.  Each subject was studied on two occasions 
separated by at least one week in a double-blinded, 
randomised cross-over design.  Subjects received an 
infusion of either ghrelin 5.0pmol/kg/min in normal saline 
or normal saline alone in random order (5 saline first, 4 
ghrelin first).  Pilot studies demonstrated that plasma ghrelin 
infusion achieves steady state within 60 min (data not 
shown).  Infusions commenced in fasted volunteers at 
08.30h (0 min) and lasted for 270 min.  At 120 min, subjects 
ate a standard test breakfast consisting of 40g cornflakes, 
250ml whole milk, 3.5g sugar (1 sachet) and 100ml fresh 
orange juice (1550 kJ, 62% carbohydrate, 13% protein and 
25% fat). Gastric emptying was estimated using the 
paracetamol absorption method (9), as paracetamol is not 
absorbed in the stomach but rapidly enters the blood stream 
from the small intestine (10).  Subjects consumed 1.5g 
paracetamol with the test breakfast. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.  Protocol for investigation of the effect of saline or ghrelin 
(5.0pmol/kg/min) infusion on appetite, food intake, gastric emptying 
and energy expenditure  
 
Blood was taken before and at 5, 10, 15, 20, 30 and 40 min 
after consumption.  Plasma paracetamol concentration was 
determined by enzymatic assay (Olympus Diagnostics, 
Southall, UK; Reagent OAR 6905) using an Olympus 
AU600 analyser.  Peak paracetamol concentration (Cmax) 
and time to peak concentration (Tmax) were determined for 
each subject and area under the curve (AUC) was calculated 
using the trapezoid rule.  Subjects reclined at 45˚ throughout 
the infusion until the buffet lunch.  At 90 and 150 min 
respectively, fasting and post-prandial respiratory quotient 
(RQ) and energy expenditure (EE) were measured by 
indirect calorimetry (Deltatrac II).  RQ is the ratio of the 
volume of CO2 produced (VCO2) to the volume of O2 
consumed (VO2).  EE was calculated as 1.32VO2(1.23RQ 
+3.81) (11).  At 240 min, while the infusions continued, a 
standard free-choice buffet was offered.  Subjects were 
instructed to eat as much as they wanted.  The choices 
consisted of chicken curry, plain boiled rice, fruit-salad, a 
variety of mini chocolate bars and fruit-flavoured sweets and 
water as required.  Food was designed to be in sufficient 
excess to satisfy all appetites and subjects were informed 
that they could take any uneaten food away with them if 
desired.  The meal was completed at a single sitting, all 
subjects having finished eating within 30 min whilst the 
infusion continued.  Food was weighed before and after the 
meal and caloric intake calculated.  At 270 min the infusion 
was discontinued.  Subjects then completed a food diary for 
the rest of the day.  Visual analogue scales rating hunger and 
how much subjects felt they could eat (possible scores 0-
10cm) were completed pre-infusion (0 min), pre-breakfast 
(120 min), pre-lunch (240 min) and after lunch (300 min).  
Positions on the scale were measured in cm and mm by a 
blinded investigator. 
Human ghrelin radioimmunassay (RIA)  Ghrelin 
immunoreactivity was measured using an antibody raised in 
a rabbit immunised with synthetic human ghrelin conjugated 
to bovine serum albumin (BSA) by gluteraldehyde and used 
at a final dilution of 1:40,000. The antibody cross-reacted 
100% with human ghrelin and human des-octanoyl3 ghrelin 
but did not cross-react with rat ghrelin or any other known 
gastrointestinal or pancreatic peptide or hormone.  125I 
labelled ghrelin was prepared using Bolton & Hunter 
reagent (Amersham International, UK) and purified by RP-
HPLC.  The assay was performed in a total volume of 0.8 ml 
of 0.06 M phosphate buffer (pH 7.2) containing 0.3% BSA 
and incubated for 3 days at 4°C before separation of free and 
antibody-bound label by sheep anti-rabbit antibody 
(Pharmacia & Upjohn, Sweden). Plasma samples were 
diluted in assay buffer (1:10 and 1:100) prior to assay of 
100µl in duplicate. A two-fold dilution curve of the plasma 
was parallel to the standard curve for human ghrelin. The 
assay could detect changes of 25 pmol/l of plasma ghrelin 
with 95% confidence limit. The inter- and intra-assay 
coefficients of variation (at 20 fmol addition) were 8.5 and 
11.2% respectively. 
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Statistics  Comparison between treatments was by paired t 
test with p<0.05 considered significant. 
Results 
The plasma GH response to increasing rates of ghrelin 
infusion is shown in figure 2.  The lowest infusion rate of 
ghrelin to significantly stimulate GH was 3.2 pmol/kg/min 
(plasma GH after 20 min at this infusion rate 18.2 ± 5.0 µg/L vs. pre-infusion 2.0 ± 1.1 µg/L; p<0.05).  A dose of 5.0 
pmol/kg/min, corresponding to approximately half-maximal 
GH stimulating dose, was chosen to study the effects of 
ghrelin on energy balance.  
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Figure 2.    Average GH response to increasing rates of ghrelin 
infusion, doubling every 20 min from 0.2 to 25.6 pmol/kg/min. * 
p<0.05, ***p<0.001. 
 
 Energy intake from the buffet lunch was increased 
by 28 ± 3.9% during ghrelin infusion compared with saline 
infusion (figure 3a: 5997 ± 413 kJ vs. saline 4713 ± 344 kJ; 
p<0.001).  Every individual consumed more calories (range: 
8.9-40.7% increase) during ghrelin infusion (figure 3b).  
There was no change in the proportion of calories obtained 
from carbohydrate, protein or fat (data not shown).  Energy 
intake for the rest of the day, estimated by analysis of food 
diaries, showed no evidence of compensatory under-eating 
following ghrelin-induced hyperphagia.  Indeed, on ghrelin 
infusion days, there was a non-significant increase in 
average energy intake for the rest of the day (6362 ± 1411 kJ 
vs. saline 5355 ± 762 kJ; p=0.5) and total 24 hours (ghrelin 
12708 ± 1838 kJ vs. saline 10396 ± 971 kJ; p=0.2).  
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Figure 3 a) mean energy intake from free choice buffet, b) individual changes in energy intake from free choice buffet and c) mean visual analogue 
scores for hunger during saline or ghrelin infusion.  * p <0.05; *** p < 0.001 
 
Analysis of visual analogue scales (VAS) confirmed 
no difference between occasions in the basal state (0 min) in 
hunger (pre-ghrelin 5.3 ± 0.8cm vs. pre-saline 5.6 ± 0.7cm; 
p=0.6) or how much subjects felt they could eat (pre-ghrelin 
5.5 ± 0.7cm vs. pre-saline 5.8 ± 0.7cm; p=0.4).  Ghrelin 
infusion then resulted in increased hunger scores compared 
to saline infusion (figure 3c) both before fixed breakfast 
(120 min: 16 ± 10% increase; p<0.05) and before lunch 
(240 min: 46 ± 20% increase; p<0.05).  The separate 
parameter of “how much could you eat right now” was also 
increased by 32 ± 14% (p<0.05) at the pre-lunch time-point 
(240 min) during ghrelin infusion.  Despite every individual 
eating more during ghrelin infusion, at 1 hour after lunch 
(300min) there was no evidence of reduced hunger (VAS: 
ghrelin 0.8 ± 0.2 vs. saline 0.9 ± 0.3cm; p=0.6) or quantity 
subjects felt they could eat (VAS: ghrelin 1.1 ± 0.2 vs. 
saline 0.9 ± 0.2cm; p=0.8). 
 
Figure 4.  Plasma paracetamol concentration in response to 
consumption of a fixed breakfast with 1.5g paracetamol during 
infusion of saline (inverted triangles, dotted line) or ghrelin (squares, 
solid line).  
No change in gastric emptying was apparent 
during ghrelin infusion as estimated by the paracetamol 
absorption test (figure 4: Tmax 27.5 ± 4.5 vs. saline 20.6 ± 
4.4 min, Cmax 86.3 ± 10.3 vs saline 87.5 ± 8.4µmol/L, AUC 
2100 ± 301 vs saline 2350 ± 282.1 µmolmin/L; p=NS).  
Ghrelin infusion did not alter fasting RQ (0.81 ± 0.03 vs. 
saline 0.82 ± 0.03), post-prandial RQ (0.88  ± 0.07 vs. 
saline 0.91 ± 0.06) or fasting total energy expenditure (4664 ± 348 kJ/day vs. saline-treated 5091 ± 427 kJ/day). The 
average post-prandial energy expenditure was lower during 
ghrelin infusion, but this difference was not significant 
(ghrelin-treated 4341 ± 239 kJ/day vs saline-treated 5506 ± 
590 kJ/day; p=0.09).  Steady-state plasma ghrelin 
concentration during ghrelin infusion was between 2 and 3 
fold that during saline infusion.  (90 min 2.6 ± 0.1 fold; 6.02 ± 0.46 vs 2.31 ± 0.28 nmol/L; 240 min 2.4 ± 0.1 fold, 5.88 ± 0.26 vs 2.49 ± 0.52 nmol/L). 
 
Discussion 
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Ghrelin is the first circulating hormone shown to 
promote feeding and adiposity following systemic 
administration in experimental animals (5;6).  We now 
demonstrate that ghrelin stimulates appetite and food intake 
potently in man.  The increase in calories consumed was 
large (28%, an additional 1284 kJ (306 kcal) in a single 
meal).  In practice much smaller consistent changes in 
energy intake over longer periods are thought to be 
involved in clinically significant weight changes.  It has 
been estimated that a 75kg man consumes 900,000kcal a 
year and that a persistent increase of 1% in energy intake 
would result in approximately 15kg weight gain over 10 
years (1).  Ghrelin concentrations in the current study were 
higher than normal circulating levels, but only just over 
twice the concentration following an overnight fast.  
Smaller changes in endogenous ghrelin may contribute to 
regulation of the smaller daily modulations of food intake 
that are required to maintain stable body weight.   
The possibility that stimulation of appetite was 
mainly secondary to stimulation of GH is unlikely.  A 
chronic increase in energy intake has been reported in 
children with accelerated growth following GH treatment 
(12), however this is thought to be secondary to increased 
metabolic demands (13) and acute changes in food intake 
have not been reported (14).  In the non GH-deficient state 
there is no consistent evidence for increased energy intake 
in response to GH (15-17).  Ghrelin-stimulated weight gain 
and adiposity are not attenuated in GH-deficient dwarf rats 
compared to intact rats (6).  Taken together, these 
observations support the notion that the stimulation of 
appetite by ghrelin in the present study is independent of 
GH. 
 In rodents ghrelin increases respiratory quotient, 
suggesting reduced fatty acid oxidation and increased 
glycolysis, which would favour fat deposition (6).  No 
change in either fasting or post-prandial respiratory quotient 
in man was detected in the present study.  A trend towards 
reduced post-prandial energy expenditure was, however, 
detected in response to ghrelin.  The systemic dose of 
ghrelin administered in rodents was a bolus of 2.4µmol/kg, 
which was associated with a rapid peak of plasma ghrelin to 
approximately 15 fold basal concentration (6).  In contrast, 
in the present study, 5.0pmol/kg/min was administered by 
infusion for 260 minutes (a total dose of only 1.3nmol/kg 
over the entire infusion) resulting in an increase in plasma 
ghrelin of just over 2-fold.  The disparity between the 
current results and those in rodents may reflect a genuine 
species difference or may reflect the lower dose and slower 
administration in the current study.  Similarly injection of a 
bolus of ghrelin has been shown to stimulate gastric 
motility in rodents, but in the current study infusion of 
ghrelin in man did not appear to alter gastric emptying.   
The peripheral hormone leptin regulates 
hypothalamic networks to inhibit food intake and body 
weight gain (2).  Absence of leptin results in extreme 
obesity in man and rodents (18).  It would be surprising if 
food intake and body weight maintenance, which are so 
important to survival, were regulated by a single inhibitory 
peripheral signal.  So far, however, no peripheral stimulator 
of the hypothalamic control of feeding has been established.  
In rodents, plasma ghrelin has been demonstrated to 
increase with fasting and fall in response to re-feeding (6) 
whilst ghrelin administration causes hyperphagia and 
obesity (5;6).  Systemic ghrelin administration in rats 
causes neuronal activation in the hypothalamic arcuate 
nucleus, a key nucleus in body weight regulation (19).  We 
now report that ghrelin stimulates food intake and appetite 
in man.   
A recent report has demonstrated reduced 
circulating ghrelin in obese compared with lean Caucasians 
and in obesity-prone Pima Indians (20).  This is analogous 
to the appetite inhibitor leptin, which is increased in obese 
individuals (2) and raises the possibility that ghrelin and 
leptin are part of a dynamic feedback system in the 
regulation of body weight.   
In conclusion our data suggest that ghrelin is a 
potentially important new peripheral signal to the brain to 
stimulate food intake in man.  Further studies are now 
required to establish the role of ghrelin in the pathogenesis 
of the energy balance dysregulation associated with obesity 
and cachexia. 
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